Sleepiz One+ vs. Capnography and Electrocardiography

Key facts

Sponsor

Sleepiz AG

Principal Investigator

Christian Neumann, Dr. med.

Zentrum für Schlafmedizin "Schlaflabor Fluntern"

Intervention

Sleepiz One+(device)

Enrollment

35 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2024

Study locations (1)

• Schlaflabor Fluntern, Zurich, Canton of Zurich, Switzerland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06872112
  A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
  Joseph C. Wu
• RECRUITINGPHASE2NCT06351345
  129 Xenon Imaging in Patients Treated With Sotatercept
  Bastiaan Driehuys
• RECRUITINGPHASE4NCT07140484
  Sotatercept in Pulmonary Arterial Hypertension
  University of Alberta
• RECRUITINGPHASE2NCT07175038
  A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
  AllRock Bio, Inc.
• RECRUITINGNCT07013149
  The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
  University of Sao Paulo General Hospital
• RECRUITINGNCT06998329
  PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
  University of Sao Paulo General Hospital
• ENROLLING BY INVITATIONPHASE2NCT06992440
  Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
  Gustavo A Heresi, MD, MS
• RECRUITINGNANCT06968962
  Comparison of Sequential to Initial Combination Therapy in PAH
  Second Affiliated Hospital, School of Medicine, Zhejiang University

See all trials for Drug- or toxin-induced pulmonary arterial hypertension →